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OPINION
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BECKER, Circuit Judge.
This appeal by Cordis Corp. (“Cordis”), the defendant in a patent infringement
lawsuit brought against it by Medtronic AVE, Inc. (“Medtronic AVE”), requires us to
2

decide whether Cordis’s claim that it has a license to use certain patents should be
determined by an arbitrator. The District Court held that the dispute was not arbitrable,
and enjoined arbitration. We will vacate and remand. Because the parties are fully
familiar with the background facts and procedural history we need not set them forth, and
limit our discussion to our ratio decidendi. 1

I.
Medtronic AVE’s suit alleges that Cordis is infringing certain patents (the
“Boneau patents”) in the field of coronary stents. Cordis asserts as one of its defenses
that it has a license to use the patents under a Settlement and License Agreement (the
“Agreement”) that it entered into with the parent corporation of Medtronic AVE to settle
prior litigation.2 At the District Court, Cordis sought to stay the proceedings in the
infringement suit and compel arbitration on the issue of its license defense. Medtronic
AVE opposed. The District Court first held that the dispute was arbitrable, but then on

1

We exercise “plenary review over legal questions concerning the applicability and
scope of an arbitration agreement.” Kilkenny v. Guy C. Long, Inc., 288 F.3d 116, 119
(3d Cir. 2002) (citing Medtronic AVE, Inc. v. Advanced Cardiovascular Sys. Inc., 247
F.3d 44, 53-54 (3d Cir. 2001)). At all events, where “the district court engages in
contract construction”—as it did here—“we exercise plenary review.” Id. (citing
Medtronic AVE, 247 F.3d at 53-54).
2

Medtronic AVE’s parent corporation, Medtronic, Inc., entered into this agreement
with Cordis prior to its acquisition of Arterial Vascular Engineering, Inc. (which, upon
acquisition, was renamed Medtronic AVE, Inc. and has since been renamed Medtronic
Vascular, Inc.).
3

reconsideration held that it was not. The District Court entered an order enjoining
arbitration, and denied Cordis’s motion to stay its proceedings. Cordis appeals to this
Court under 9 U.S.C. § 16(a)(1)(A), which provides for interlocutory review of an order
“refusing a stay of any action” pending arbitration.

The contract dispute at issue is governed by state law (New York law, under §
11.04 of the Agreement), though we are also guided by cases decided under the Federal
Arbitration Act, codified as amended at 9 U.S.C. §§ 1-16. These cases, which lay down
the overarching principles by which arbitration clauses are interpreted, are Moses H.
Cone Memorial Hospital v. Mercury Construction Corp., 460 U.S. 1, 24 (1983)
(explaining that there is a “liberal federal policy favoring arbitration”); AT&T
Technologies, Inc. v. Communications Workers of America, 475 U.S. 643, 650 (1986)
(“‘[An] order to arbitrate . . . should not be denied unless it may be said with positive
assurance that the arbitration clause is not susceptible of an interpretation that covers the
asserted dispute.’” (quoting United Steelworkers of Am. v. Warrior & Gulf Navigation
Co., 363 U.S. 574, 582-83 (1960))); First Options of Chicago, Inc. v. Kaplan, 514 U.S.
938, 943 (1995) (“[A]rbitration is simply a matter of contract between the parties; it is a
way to resolve those disputes—but only those disputes—that the parties have agreed to
submit to arbitration.”); and Suter v. Munich Reinsurance Co., 223 F.3d 150, 155 (3d
Cir. 2000) (“‘Any doubts concerning the scope of arbitrable issues should be resolved in
favor of arbitration.’” (quoting Patten Sec. Corp. v. Diamond Greyhound & Genetics,
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Inc., 819 F.2d 400, 405-07 (3d Cir. 1987))).
II.
These are useful guidelines, and they are all easily satisfied in this case because
we conclude that the contract clearly makes this dispute arbitrable. Two provisions from
the agreement command our attention. First is language from Article V, which is
captioned “Resolution of Patent Disputes”:
In addition [to other provisions specific to certain enumerated patents], any
dispute, claim, or controversy arising under this Agreement which relates to
patent matters, the resolution of which is not specifically provided for [in
another part of the Agreement], shall be resolved pursuant to binding
arbitration . . . .
Agreement § 5.02. Second is language from Article X, which is captioned “Alternative
Dispute Resolution”:
Any dispute, claim, or controversy (“disputes”) arising from or relating to
this Agreement or alleged breaches thereof (excluding all disputes related
to patent matters, such as all disputes related in whole or in part to a
Licensed Patent or any patent alleged to be a Licensed Patent or related to
whether a product is in the Field, which disputes shall be resolved pursuant
to Article V) . . . shall be resolved by binding Alternative Dispute
Resolution . . . .
Agreement § 10.01. Article X and Article V provide (in sections we have not
reproduced) somewhat different procedures for dispute resolution.
We agree with Cordis that Article X establishes a seamless division of “dispute[s],
claim[s], [and] controvers[ies]” into two classes: Those that are arbitrable under Article
X and those that are arbitrable under Article V, the latter being “disputes related to patent
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matters.” So long as a dispute “aris[es] from or relat[es] to” the Agreement, it must be
arbitrated under either Article V or Article X. There is simply no basis in the plain
language of the Agreement for Medtronic AVE ’s contention that there is an unspoken
third category of disputes (to which putative class the instant dispute would belong) that
is not governed by either Article V or Article X. This is not “Scylla and Charybdis”
where one may pass in the narrow channel between; rather, in the Agreement, “all roads
lead to Rome,” for the license issue is either subject to Article V, or if it is not subject to
Article V, then it is necessarily subject to Article X.
These conclusions, of course, depend upon the accuracy of the proposition that the
dispute in question “aris[es] from or relat[es] to” the Agreement. The District Court held
on reconsideration that, this being a licensing agreement, only disputes about licensed
patents would “aris[e] from or relat[e] to” the Agreement. Since the Court concluded
that the Boneau patents were not licensed under the Agreement (and hence not covered
by the Agreement), it held that this dispute did not arise from the Agreement, and hence
was not arbitrable. Medtronic AVE endorses this reasoning on appeal. We disagree.
Preliminarily, we note the longstanding rule that courts “have no business
weighing the merits” of the issue proposed to be arbitrated. United Steelworkers of Am.
v. Am. Mfg. Co., 363 U.S. 564, 568 (1960). This was, as the District Court recognized,
the effect of its ruling on reconsideration. This alone does not render the District Court’s
analysis incorrect, for there may be cases in which a preliminary ruling on the merits is
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unavoidable. In this case, however, a review of (and ruling on) the merits was entirely
unnecessary because the District Court erred in its construction of the Agreement’s
“arising from” language.
We give an expansive interpretation to “arising from.” As we explained in
Battaglia v. McKendry, 233 F.3d 720, 727 (3d Cir. 2000), “when phrases such as ‘arising
under’ and ‘arising out of’ appear in arbitration provisions, they are normally given broad
construction.” Coupled with our usual strong presumption in favor of arbitrability, see,
e.g., Sharon Steel Corp. v. Jewell Coal & Coke Co., 735 F.2d 775, 778 (3d Cir. 1984), a
clause providing for the arbitration of all matters “arising from” an agreement
overwhelmingly suggests that a given dispute is arbitrable. Cordis also directs us to
interpretations of similar language in a variety of other arbitration agreements. For
example, in Sweet Dreams Unlimited, Inc. v. Dial-A-Mattress International, Inc., 1 F.3d
639, 642 (7th Cir. 1993), the Court interpreted an arbitration clause applying to disputes
“arising out of the agreement” as covering “any dispute between the contracting parties
that is in any way connected with their contract.”3

3

Two of the cases cited by Cordis address whether disputes about the very formation of
the contract that contains the arbitration clause are arbitrable. These decisions follow the
Supreme Court’s decision in Prima Paint Corp. v. Flood & Conklin Mfg. Co., 388 U.S.
395, 403-04 (1967), which held that apart from issues that go to the making of the
agreement to arbitrate (i.e., the arbitration clause itself), disputes about the very formation
of the contract are arbitrable. It seems to us that if this marks the outer limit of what
issues are arbitrable under an “arising from” clause, then the dispute in this case is
comfortably in the heartland of disputes that ought to be arbitrated under the language of
the Agreement.
7

Moreover, as arbitration clauses are close cousins of jurisdictional provisions, we
can look to the “arising under” language of Article III, section 2 of the United States
Constitution. “A case ‘arises’ under the Constitution or a law of the United States . . .
whenever its correct decision depends on the construction of either.” Black’s Law
Dictionary 108 (6th ed. 1990). Adapting that principle to this case, a dispute will
“aris[e] from” the Agreement whenever the correct resolution of the dispute depends on
the construction of the Agreement. The validity of Cordis’s license defense
unquestionably turns on the construction of the Agreement.
This interpretation is confirmed by the language of the Agreement itself. As
quoted above, § 10.01 of the Agreement carves out (in the “excluding . . .” clause)
certain disputes from the coverage of Article X. Of course, something can be excluded
only if it would otherwise be included, and so disputes “related to patent matters, such as
disputes related in whole or in part to a Licensed Patent or any patent alleged to be a
Licensed Patent” must be a subset of the larger set of disputes “arising from or relating to
this Agreement or alleged breaches thereof.” Because Cordis seeks to arbitrate a
“dispute related . . . in part to . . . [a] patent alleged to be a Licensed Patent,” the question
whether Cordis enjoys a license to the Boneau patents does indeed arise under the
Agreement, and hence is arbitrable.
New York law, which governs our interpretation of the Agreement,
unquestionably supports this interpretation. In Shaw Group Inc. v. Triplefine

8

International Corp., 322 F.3d 115, 120 (2d Cir. 2003), the Court of Appeals for the
Second Circuit applied New York law to interpret an arbitration clause which provided
that “[a]ll disputes [between the parties] concerning or arising out of this Agreement
shall be referred to arbitration.” The Court interpreted the “arising out of” language very
broadly, holding that it required referring even the issue of arbitrability to the arbitrator.
See id. at 121-25. Furthermore, in that discussion, the Court noted that in Smith Barney
Shearson Inc. v. Sacharow, 689 N.E.2d 884 (N.Y. 1997), the New York Court of
Appeals had broadly construed language providing for the arbitration of “any
controversy.” Clearly “any dispute, claim, or controversy” (as used in Article X of the
Agreement) is at least as expansive as “any controversy” (as used in the Smith Barney
Shearson agreement).
Moreover, Medtronic AVE has advanced no plausible argument why the “arising
from” language should not be construed this way. By contrast, for example, the plaintiff
in Battaglia—who, like Medtronic AVE, sought to avoid arbitration—advanced an
argument on appeal that the structure of the agreement at issue rendered the arbitration
clause inapplicable to certain matters. See Battaglia, 233 F.3d at 728-29. Medtronic
AVE offers no such argument, yet the requirement of “positive assurance” that an
arbitration clause is inapplicable places the burden squarely on Medtronic AVE in this
case. See AT&T Techs., 475 U.S. at 650 (“‘[An] order to arbitrate . . . should not be
denied unless it may be said with positive assurance that the arbitration clause is not
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susceptible of an interpretation that covers the asserted dispute.’” (quoting Warrior &
Gulf Navigation Co., 363 U.S. at 582-83)). We cannot plausibly say—let alone say with
“positive assurance”—that the “arising from” language does not require arbitration of the
license issue.
Finally, we note that our decision comports with the long line of cases that hold
that arbitrability is ultimately a question for the arbitrator to resolve. See Sharon Steel,
735 F.2d at 779 (“[T]he Federal Arbitration Act gives the arbitrator the power to
determine the scope of the arbitration clause as well as the substantive merits of the
claim.” (citing Acevedo Maldonado v. PPG Indus., 514 F.2d 614, 617 (1st Cir.1975)).

III.
We limit our holding to the arbitrability of the existence vel non of a license to the
Boneau patents, but we also note Cordis’s counsel’s position at oral argument that Cordis
seeks to arbitrate only the license issue, and does not argue that Medtronic AVE’s entire
lawsuit should be referred to arbitration.4 We need not decide whether arbitration in this
case should proceed under the provisions of Article V or Article X; the parties may be
able to agree between themselves, and if not, the District Court should have the
4

Medtronic AVE protests that ruling in Cordis’s favor makes virtually any dispute
between the parties arbitrable. As this case demonstrates, Medtronic AVE is correct that
disputes between the parties in which the Agreement is invoked are arbitrable—though
only in part, because only those issues “arising from” the Agreement are arbitrable. This
is a far cry from construing the Agreement to give the parties carte blanche to arbitrate
the whole of any dispute between them, which we of course do not do.
10

opportunity to resolve that issue in the first instance. And we of course intimate no view
on the merits of the controversy. See Am. Mfg. Co., 363 U.S. at 567-68.
The order of the District Court will be vacated, and the case remanded with
instructions for the District Court to enter an order compelling arbitration of the license
issue. The mandate shall issue forthwith.
AMBRO, Circuit Judge, concurring
I concur in the outcome reached by my colleagues, which vacated the District
Court’s denial of arbitration. I agree that the District Court erred in reaching the merits
of the dispute to decide arbitrability. I also agree that “all roads lead to Rome,” i.e.,
arbitration (though there may be one more road not mentioned in Judge Becker’s
opinion). But I disagree with my colleagues’ blanket statement that arbitrability itself is a
question for the arbitrator.
It is unnecessary to leave the resolution of arbitrability to the arbitrator in this
case. In Sharon Steel Corp. v. Jewell Coal and Coke Co., 735 F.2d 775, 779 (3d Cir.
1984), we did so because “[t]he heart of the problem in th[at] case [wa]s the fact that the
question of arbitrability [wa]s intertwined with the merits . . . .” We do not have the
same problem here because, as Judge Becker notes, reviewing the merits is wholly
unnecessary to decide the question of arbitrability. As a result, the scope (or
applicability) of an arbitration agreement is a question for judicial determination.
Medtronic AVE, Inc. v. Advanced Cardiovascular Systems, Inc., 247 F.3d 44, 54 (3d Cir.
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2001) (“[Under the Federal Arbitration Act,] the issue of whether the dispute is within
the scope of the agreement requires district court resolution.” (citing AT&T Techs., Inc. v.
Communication Workers of Am., 475 U.S. 643, 649 (1986); PaineWebber Inc. v.
Hartmann, 921 F.2d 507, 510-11 (3d Cir. 1990))). There is no harm here, however, for
my colleagues and I do decide that the dispute is arbitrable rather than leaving that
decision to the arbitrator.
I make one other comment–less substantive but necessarily lengthier. It is that
there may be yet another “road to Rome.” I begin for background with the dispute
(which, of course, we are not deciding). At base, it is whether, under the Settlement and
License Agreement, Cordis has a license to the Boneau patents owned by Medtronic
AVE.5 If so, Cordis is not infringing these patents by using them.
Medtronic claims that the Boneau patents are not licensed to Cordis. It points to §
1.03 of the Agreement, which defines the patents subject to its cross-licensing
provisions. Section 1.03 provides that licensed patents under the Agreement “means any
and all patents . . . that are . . . owned by Medtronic or its Affiliates . . . on the Effective
Date.” Medtronic AVE emphasizes that, on “the Effective Date [of the
Agreement]”–November 4, 1997–the Boneau patents were not owned by Medtronic or

5

As noted by Judge Becker, Medtronic AVE was formerly known as Arterial Vascular
Engineering, Inc. (“AVE”). It was acquired by Medtronic Inc. (“Medtronic”) in January
1999. Medtronic gave AVE a new name–Medtronic AVE. Medtronic AVE (the
subsidiary), and not Medtronic (the parent), is the appellee in this case. It was Medtronic,
and not Medtronic AVE, who signed the Agreement.
12

its Affiliates. Appellee’s Br. at 29-30. They belonged to AVE, who was not affiliated
with Medtronic at that time. Id. at 30. Thus, Medtronic AVE argues, Medtronic could
not have licensed out the patents it did not own as of November 4, 1997. Id. at 30-31.
Cordis counters by pointing out that § 1.01 of the Agreement defines “Affiliate”
as “any entity that is controlled by [Medtronic], on the Effective Date or, subject to
Section[] 11.02(d) or 11.02(e)6 hereof, becomes controlled by such party, after the
Effective Date.” Appellant’s Br. at 13 (footnote and emphasis added). Cordis claims that
because AVE, the owner of the Boneau patents, became controlled by Medtronic after
November 4, 1997, it is an “Affiliate” of Medtronic under the Agreement whose patents
(including Boneau patents) can be licensed by Cordis. Id.
Medtronic AVE does not dispute “Affiliate” includes after-acquired companies
such as itself under §1.01.7 It argues, however, that §1.01 merely meant to confer the
benefit of the cross-license to after-acquired companies without any corresponding
6

Section 11.02(e) is not relevant to my analysis. Thus I do not quote it. Section
11.02(d) provides that “[i]f one of the parties hereto acquires a Major Competitor . . .,
then such party’s license rights shall not be extended to cover any products of such Major
Competitor.” AVE, the predecessor of Medtronic AVE, is identified in §1.05 of the
Agreement as one of the Major Competitors of the signatory parties. Thus, applied to our
facts the provision presumably would read: “If [Medtronic] acquires [AVE] . . ., then
[Medtronic’s] license rights shall not be extended to cover any products of [AVE].” In
light of the fact that Medtronic owns AVE, the sentence is narrishkeit. To make sense of
it, should, for example, “such party’s” have been “J&J’s”, or should “license rights” have
been “rights as licensor”?
7

Thus, Medtronic AVE does not challenge the District Court’s ruling that Medtronic
AVE is bound by a valid arbitration agreement. It instead claims that the particular issue
Cordis seeks to arbitrate is not within the scope of the arbitration agreement.
13

obligation to cross-license their patents (such as the Boneau patents). Appellee’s Br. at
30. Cordis counters that after-acquired companies are subject to the obligation of
licensing their patents, by pointing to §11.02(a), which provides that the Agreement
“shall be binding upon and inure to the benefit of Medtronic . . . and [its] Affiliates,” and
“Affiliates” include after-acquired companies. Medtronic AVE does not respond to this
argument. It, however, claims that its patents are not covered under §11.02 because
§11.02(d) (the scrambled carve-out provision quoted in note 2) specifically refers to the
products, and not the patents, of major competitors.
I agree with Cordis that this dispute is a merits question that should be decided by
the arbitrator, not by our Court.8 If the arguments proceed as set out above, the
resolution of that dispute turns on how to read § 1.01 and § 11.02 of the Agreement.
Insofar as the resolution of the issue depends on the reading of §1.01 (“Affiliate”), the
issue is arbitrable under Article X, which covers “[a]ny dispute, claim, or controversy . . .
arising from or relating to this Agreement . . . .” To the extent that the dispute involves
interpreting what obligation, if any, is imposed on after-acquired affiliates by § 11.02, the
issue is subject to the arbitration clause in § 11.02(g), which provides that “[a]ny dispute,
claim, or controversy arising under the provisions of this Section 11.02 shall be resolved

8

Medtronic AVE also argues, and the District Court agreed, that the two amendments
to the Agreement support the conclusion of non-arbitrability. The amendments purported
to grant the parties license rights to patents owned by specific after-acquired companies.
The amendments are, if anything, evidence with respect to the underlying dispute, not the
arbitrability of it.
14

pursuant to binding arbitration . . . under the provisions of Article X . . . .”
In any event, and under any interpretation, the analytical path leads to arbitration.
Thus I concur.
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